Bicara Therapeutics Inc. (BCAX) earnings
BCAX earnings moved a median of +2.43% by the close. Quarterly and annual BCAX reports and results, each read against the price at its own news timestamp. Back to the BCAX overview →
19 measured BCAX earnings events.
Where these BCAX earnings landedvs 18 measured BCAX earnings reactions
| Middle 50% of BCAX earnings reactions | -1.93% to +4.28% |
|---|---|
| Median reaction (to close) | +2.43% |
| Measured reactions | 18 |
Point-in-time · zero look-ahead
Half of the 18 BCAX earnings events with a measured close landed between -1.93% and +4.28%; 67% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update | Press release | -1.69% | +12.13% | |
| Form 10-Q Bicara Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | -1.74% | +4.30% | |
| Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET | Press release | -1.32% | -12.47% | |
| Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth | Press release | +11.54% | +4.21% | |
| Form 10-Q Bicara Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.06% | +2.63% | |
| Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET | Press release | +0.27% | -0.53% | |
| Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | -1.33% | +1.91% | |
| Form 10-Q Bicara Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.02% | -2.40% | |
| Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET | Press release | +0.42% | +5.04% | |
| Form 10-K Bicara Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | -0.08% | +2.47% | |
| Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026 | Press release | +0.19% | +2.38% | |
| Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | +3.38% | -5.75% | |
| Form 10-Q Bicara Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.40% | +6.74% | |
| Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | +0.45% | — | |
| Form 10-Q Bicara Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.52% | +6.58% | |
| Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | +0.00% | -8.10% | |
| Form 10-Q Bicara Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.83% | +3.79% | |
| Form 10-K Bicara Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | +6.05% | +0.07% | |
| Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | -0.67% | -6.52% |
Keep exploring
More BCAX: analyst actions → · SEC filings → · BCAX overview →